Novartis, Dren Bio Ink Potential $3B Deal for Anti-Myeloid Bispecific Antibodies for Cancer

Novartis continues its dealmaking spree with a bet on Dren Bio’s Targeted Myeloid Engager and Phagocytosis platform to develop bispecific antibodies in oncology.